NCT05257122

A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer

A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy

Detailed description

This study is an open Label, non-randomized, single-arm and multi-centered phase II clinical trial. It plans to evaluate the safety and efficacy of fruquintinib in advanced pancreatic cancer patients who failed second-line gemcitabine or 5-FU based chemotherapy.

Conditions

• Advanced Pancreatic Carcinoma

Interventions

Type	Name	Description
DRUG	Fruquintinib	Fruquintinib 5mg qd, d1-21, q28d

Timeline

• Start date: 2022-02-01
• Primary completion: 2023-09-01
• Completion: 2024-02-01
• First posted: 2022-02-25
• Last updated: 2022-02-25

Locations

1 site across 1 country: China